Research Paper Volume 13, Issue 24 pp 25903—25919
METTL14 benefits the mesenchymal stem cells in patients with steroid-associated osteonecrosis of the femoral head by regulating the m6A level of PTPN6
Figure 2. METTL14 was responsible for the aberrant m6A modification in BMSCs from SONFH patients. (A) The m6A content in total RNA of SONFH tissues and BMSCs (n = 20) and normal tissues and BMSCs (n = 20). (B) mRNA levels of m6A modification associated genes in SONFH tissues and BMSCs and normal tissues and BMSCs. (C) IHC assay determined the expression of METTL14 in osteonecrosis tissues and normal tissues. Scale bar = 100 μm. (D) The protein levels of METTL14 in SONFH BMSCs and normal BMSCs were measured by western blot. (E, F) The efficiency of METTL14 overexpression in SONFH BMSCs was confirmed by qRT-PCR and western blot analysis. (G) Quantitative m6A methylation assay was used to define the effect of METTL14 overexpression on the level of m6A modification in BMSCs from SONFH patients. *P < 0.05, **P < 0.01, ***P < 0.001, n.s is no significance.